» Articles » PMID: 8499917

Genetic Linkage Between Von Hippel-Lindau Disease and Three Microsatellite Polymorphisms Refines the Localisation of the VHL Locus

Overview
Journal Hum Mol Genet
Date 1993 Mar 1
PMID 8499917
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Von Hippel-Lindau (VHL) disease is a dominantly inherited familial cancer syndrome characterised by the development of retinal and central nervous system haemangioblastomas, renal cell carcinoma and phaeochromocytoma. The gene for VHL disease has been mapped to chromosome 3p25-p26 and presymptomatic diagnosis using linked DNA markers is available. We have previously mapped the VHL disease gene to a 4 cM interval between D3S1250 and D3S18. To increase access to presymptomatic diagnosis and to accelerate progress towards isolating the VHL disease gene we attempted to identify microsatellite DNA markers linked to the disease gene by genetic linkage analysis in 29 families. We found significant linkage between the VHL disease gene and dinucleotide (CA) repeat polymorphisms at D3S1038 (Zmax = 22.24 at theta = 0.01, CI 0.0001-0.06), D3S1110 (Zmax = 11.32 at theta = 0.07, CI 0.03-0.14) and D3S651 (Zmax = 7.73 at theta = 0.04, CI 0.008-0.13). We localised D3S1038 between D3S1250 and D3S601, and mapped D3S1110 and D3S651 centromeric to D3S1250. Multipoint linkage analysis mapped the VHL disease locus between D3S1038 and D3S18 with the maximum likelihood at D3S601. There was no evidence of locus heterogeneity. This study has (i) identified three microsatellite DNA markers in chromosome 3p25 linked to the VHL disease gene and (ii) narrowed the target region for the isolation of the VHL disease gene by positional cloning techniques. These findings will improve the management of families with VHL disease by improving the accuracy and availability of presymptomatic diagnosis using linked DNA markers, and will accelerate progress towards isolating the VHL disease gene.

Citing Articles

Genome editing and cancer therapy: handling the hypoxia-responsive pathway as a promising strategy.

Stampone E, Bencivenga D, Capellupo M, Roberti D, Tartaglione I, Perrotta S Cell Mol Life Sci. 2023; 80(8):220.

PMID: 37477829 PMC: 10361942. DOI: 10.1007/s00018-023-04852-2.


The genetic basis of kidney cancer: a metabolic disease.

Linehan W, Srinivasan R, Schmidt L Nat Rev Urol. 2010; 7(5):277-85.

PMID: 20448661 PMC: 2929006. DOI: 10.1038/nrurol.2010.47.


The ubiquitin system, disease, and drug discovery.

Petroski M BMC Biochem. 2008; 9 Suppl 1:S7.

PMID: 19007437 PMC: 2582801. DOI: 10.1186/1471-2091-9-S1-S7.


Linkage disequilibrium mapping in the Newfoundland population: a re-evaluation of the refinement of the Bardet-Biedl syndrome 1 critical interval.

Fan Y, Green J, Ross A, Beales P, Parfrey P, Davidson W Hum Genet. 2004; 116(1-2):62-71.

PMID: 15517396 DOI: 10.1007/s00439-004-1184-9.


Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization.

Bissig H, Richter J, Desper R, Meier V, Schraml P, Schaffer A Am J Pathol. 1999; 155(1):267-74.

PMID: 10393858 PMC: 1866676. DOI: 10.1016/S0002-9440(10)65120-6.